title: Clinical, histological, and biochemical predictors of postsurgical neuropathic pain.
abstract: Surgical nerve injury sometimes leads to chronic postsurgical neuropathic pain (CPSNP). The risk factors for this condition are not well understood. We prospectively assessed 46 patients scheduled for iliac crest bone harvest, 2 days (D2) and 3 months (M3) after surgery, to determine the time course of nerve fiber degeneration and expression of the TNF-α and NGF genes in skin punch biopsies. Mechanical and thermal detection and pain thresholds were evaluated at D2 and M3, by quantitative sensory testing. Skin punch biopsies were also obtained from the thighs ipsilateral and contralateral to iliac crest bone harvest. Intraepidermal nerve fiber density (IENFD) and cutaneous TNF-α and NGF gene expression were analyzed. Forty-five volunteers matched for age, sex, skin color were examined as controls. Chronic postsurgical neuropathic pain was defined as pain in an area of hypesthesia with a positive Douleur Neuropathique 4 questionnaire score. Overall, 73% (N = 32) of patients developed hypesthesia and 40% (N = 13) of these patients had developed CPSNP at M3. Quantitative sensory testing results, IENFD, and skin TNF-α and NGF gene expression at D2 and M3 did not differ between patients with and without CPSNP. However, in patients with CPSNP, burning, compression, and pain provoked by brushing were correlated with IENFD at M3, suggesting a possible association between partial nerve lesions and more intense CPSNP, than with total nerve lesion. Furthermore, preoperative pain and opioid use were higher in patients who developed CPSNP than in those without CPSNP. These findings suggest that the predictors of CPSNP development are clinical rather than histological or biochemical.
authors.affiliation: Service d'Anesthésie Réanimation Chirurgicale, Hôpital Raymond-Poincaré, AP-HP, Université de Versailles St-Quentin, Garches, France INSERM U-987, Centre d'Evaluation et de Traitement de la Douleur, Hôpital Ambroise Paré, Boulogne-Billancourt, France; Université Versailles Saint-Quentin, Versailles, France Department of Neurology, University of Würzburg, Würzburg, Germany Service d'orthopédie, Hôpital Raymond-Poincaré, AP-HP, Université de Versailles St-Quentin, Garches, France Service de Biochimie, Hôpital Raymond-Poincaré, Garches, France.
authors.forename: Valéria
authors.initials: V
authors.lastname: Martinez
authors.forename: Nurcan
authors.initials: N
authors.lastname: Üçeyler
authors.forename: Skander
authors.initials: S
authors.lastname: Ben Ammar
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Alvarez
authors.forename: Fabrice
authors.initials: F
authors.lastname: Gaudot
authors.forename: Claudia
authors.initials: C
authors.lastname: Sommer
authors.forename: Didier
authors.initials: D
authors.lastname: Bouhassira
authors.forename: Dominique
authors.initials: D
authors.lastname: Fletcher
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D015870:Gene Expression / Q000502:physiology; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D006919:Hydroxyzine / Q000627:therapeutic use; D006930:Hyperalgesia / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000627:therapeutic use; D009294:Narcotics / Q000627:therapeutic use; D009412:Nerve Fibers / Q000473:pathology; D020932:Nerve Growth Factor / Q000235:genetics / Q000378:metabolism*; D009437:Neuralgia / Q000209:etiology / Q000378:metabolism* / Q000473:pathology*; D010147:Pain Measurement; D017288:Pain Threshold / Q000502:physiology; D010149:Postoperative Pain / Q000150:complications / Q000378:metabolism* / Q000473:pathology*; D012867:Skin / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism*; D055815:Young Adult
chemical_list: D006634:Histamine H1 Antagonists; D009294:Narcotics; D014409:Tumor Necrosis Factor-alpha; D006919:Hydroxyzine; D009020:Morphine; D020932:Nerve Growth Factor